These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36573628)

  • 21. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
    Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
    Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histomorphological features of mucormycosis with rise and fall of COVID-19 pandemic.
    Ganesan N; Sivanandam S
    Pathol Res Pract; 2022 Aug; 236():153981. PubMed ID: 35749915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal Effect of Nanoparticles against COVID-19 Linked Black Fungus: A Perspective on Biomedical Applications.
    Gurunathan S; Lee AR; Kim JH
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. COVID19 associated mucormycosis: Is GRP78 a possible link?
    Gumashta J; Gumashta R
    J Infect Public Health; 2021 Oct; 14(10):1351-1357. PubMed ID: 34538732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucormycosis in COVID-19: The Indian scenario.
    Ghosh R; Roy D; Benito-León J
    J Mycol Med; 2022 Aug; 32(3):101275. PubMed ID: 35364402
    [No Abstract]   [Full Text] [Related]  

  • 26. Multimodal analysis of the COVID-19-associated mucormycosis outbreak in Delhi, India indicates the convergence of clinical and environmental risk factors.
    Chowdhary A; Gupta N; Wurster S; Kumar R; Mohabir JT; Tatavarthy S; Mittal V; Rani P; Barman P; Sachdeva N; Singh A; Sharma B; Jiang Y; Cuomo CA; Kontoyiannis DP
    Mycoses; 2023 Jun; 66(6):515-526. PubMed ID: 36790120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021.
    Buil JB; van Zanten ARH; Bentvelsen RG; Rijpstra TA; Goorhuis B; van der Voort S; Wammes LJ; Janson JA; Melchers M; Heusinkveld M; Melchers WJG; Kuijper EJ; Verweij PE
    Euro Surveill; 2021 Jun; 26(23):. PubMed ID: 34114540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Five probable factors responsible for the COVID-associated mucormycosis outbreak in India.
    Ravindra K; Ahlawat A
    Int J Infect Dis; 2021 Nov; 112():278-280. PubMed ID: 34592439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucormycosis in India: unique features.
    Chakrabarti A; Singh R
    Mycoses; 2014 Dec; 57 Suppl 3():85-90. PubMed ID: 25187095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COVID-19 associated mucormycosis - An emerging threat.
    Chao CM; Lai CC; Yu WL
    J Microbiol Immunol Infect; 2022 Apr; 55(2):183-190. PubMed ID: 35074291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pediatric Mucormycosis and COVID-19.
    Yadav S
    J Contemp Dent Pract; 2021 Aug; 22(8):855. PubMed ID: 34753834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India.
    Rocha ICN; Hasan MM; Goyal S; Patel T; Jain S; Ghosh A; Cedeño TDD
    Trop Med Int Health; 2021 Sep; 26(9):1016-1018. PubMed ID: 34117677
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mucor in a Viral Land: A Tale of Two Pathogens.
    Sen M; Lahane S; Lahane TP; Parekh R; Honavar SG
    Indian J Ophthalmol; 2021 Feb; 69(2):244-252. PubMed ID: 33463566
    [TBL] [Abstract][Full Text] [Related]  

  • 34. "Black fungus": a perspective on the coronavirus disease 2019 (COVID-19)-associated rhino-orbital mucormycosis epidemic in India.
    Thakar A; Lal D
    Int Forum Allergy Rhinol; 2021 Aug; 11(8):1278-1279. PubMed ID: 34185968
    [No Abstract]   [Full Text] [Related]  

  • 35. Mucormycosis in the COVID-19 Environment: A Multifaceted Complication.
    Sharma R; Kumar P; Rauf A; Chaudhary A; Prajapati PK; Emran TB; Gonçalves Lima CM; Conte-Junior CA
    Front Cell Infect Microbiol; 2022; 12():937481. PubMed ID: 35923801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review on SARS-CoV-2-associated fungal coinfections.
    Soni S; Namdeo Pudake R; Jain U; Chauhan N
    J Med Virol; 2022 Jan; 94(1):99-109. PubMed ID: 34570905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Manipulation in Mucorales and New Developments to Study Mucormycosis.
    Lax C; Cánovas-Márquez JT; Tahiri G; Navarro E; Garre V; Nicolás FE
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mucormycosis of the Middle Ear and Neck Post COVID 19.
    Dongol K; Rayamajhi P; Pradhananga RB; Dulal M; Sedhai M; Gurung B
    J Nepal Health Res Counc; 2023 Mar; 20(3):812-815. PubMed ID: 36974881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors.
    Hassan MIA; Voigt K
    Med Mycol; 2019 Apr; 57(Supplement_2):S245-S256. PubMed ID: 30816980
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.